Skip to main content

Michael Monko, Frank Burgaezy, Roger Durst, Bernard Kolodziej, Bruker AXS, Quark Biotech, Agilent, ABI, DuPont, MDS Sciex

People

Serologicals last week named Michael Monko as vice president of sales for its research products segment. Monko previously spent 20 years in various sales positions at Invitrogen. He most recently served as Invitrogen's senior director of sales force effectiveness. He holds an MBA from Babson College and a BS in biochemistry from the University of New Hampshire. Monko will be based in Serologicals' Temecula, Calif., office.


Bruker AXS announced this week the promotions of Frank Burgaezy, Roger Durst, and Bernard Kolodziej to executive vice presidents. Burgaezy now leads the Bruker AXS X-ray diffraction and X-ray fluorescence businesses, and has global responsibility for marketing at Bruker AXS. Durst leads the Bruker AXS X-ray single crystal diffraction business, and as chief technology officer heads global R&D. Kolodziej leads the global finance function and European operations, as well as several subsidiaries of Bruker AXS.

BioCommerce Briefs

Bruker AXS to Acquire French X-Ray Analysis Software Firm

Bruker AXS will acquire French X-ray analysis-software company Socabim for an undisclosed sum, the company said this week.

Socabim has already been providing software for X-ray diffraction and X-ray fluorescence materials analysis to Bruker AXS. Bruker plans to merge Socabim with its own French subsidiary near Paris.

Socabim employees are expected to remain with the company following the acquisition, which is expected to close in the first quarter of 2006.

"We believe that with the addition of the Socabim technology and R&D team, our products can accelerate their 'time-to-market,' and our X-ray systems for advanced research and process analysis [...] will be even more powerful and user-friendly," said Frank Burgazy, managing director of Bruker AXS and president of the French subsidiary, in a company statement.


Quark Biotech Becomes Certified CGH Service Shop for Agilent Arrays

Quark Biotech has become a certified service provider for Agilent Technologies' microarrays used for array comparative genomic hybridization services, the company said this week.

Quark has been a certified service provider for Agilent's gene expression microarrays since April.

The certification includes sample receipt, labeling, and the use of Agilent's CGH platform for hybridization and data analysis, Quark said in a statement.


ABI, DuPont to Co-Develop Pathogen Detection Tools for Food Industry

Applied Biosystems and DuPont Qualicon will co-develop new pathogen-detection applications for the food industry, the companies said this week.

The new products will be based on DuPont's Bax system, which uses PCR to detect microorganisms in food. ABI's TaqMan real-time PCR technology will add additional capabilities to the system, such as quantitation, strain discrimination, and detection of new organisms.

DuPont Qualicon is a DuPont business based in Wilmington, Del.


MDS Sciex to Move Beyond Mass Spec with Cell Analysis Platform

MDS Sciex is diversifying its product offerings beyond its flagship line of mass spectrometry instruments to include cellular analysis, the company said at IBC's Drug Discovery Technology conference, held in Boston last week.

MDS Sciex, the analytical instruments division of publicly traded biotech firm MDS, was previewing its newest product, CellKey, at the meeting. A company official told BioCommerce Week's sister publication Cell-Based Assay News that it plans to officially launch the product next month at the Society for Biomolecular Screening conference in Geneva.

CellKey is a label-free cellular analysis platform based on cellular dielectric spectroscopy. In this technique, cells are grown on electrodes embedded in microwell plates, and a constant low-level voltage is applied. A detection instrument senses changes in electrical impedance that result from changes in cell morphology, confluence, adherence, and interactions.


Note to Subscribers:
BioCommerce Week
will not publish on Aug. 25 or Sept. 1. The next issue of the newsletter will appear on Sept. 8.
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.